Skip to content
Preprint · OA via OpenAlex

Effect of senolytic anti-aging compounds in Down syndrome-driven senescence

Raquel Alves da Silva

Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · 2021

Abstract

Down Syndrome (DS) is a disease characterized by a trisomy of chromosome 21, with thousands of new cases being reported every year. With the development of technology and medicine, life expectancy for these patients has been steadily increasing, making noticeable the development of premature age-related features and pathologies. Aneuploidy – an abnormal number of chromosomes resulting from chromosome mis-segregation during cell division – has been associated with several cellular phenotypes, including senescence(definition). In recent years, evidence has pointed to the accumulation of senescent cells along aging as a major reason for the development of several age-associated diseases. This suggests that senescence accrual might contribute to the premature aging phenotypes of DS. However, quantitative analysis of senescence in DS along advancing age is missing so far. To fill this gap, we used human fibroblast cultures from differently aged DS and healthy donors and performed quantitative analysis of several senescence markers. We found that, for all markers, the number of senescent cells in DS cultures was higher when comparing to euploid age-matched counterparts. Moreover, aging was also accompanied by senescence accrual in both healthy and trisomic fibroblasts. Having established the senescence prevalence in DS, we asked whether the use of senolytics(definition) – compounds that selectively eliminate senescent cells – could prove efficient in this context. To this end, we treated the cells with a combination of the well-established senolytic compounds, Dasatinib and Quercetin. We observed that this therapeutical approach decreased the senescence load measured through distinct markers in DS cultures to equivalent levels of euploid counterparts. However, this was accompanied by an impairment in proliferative capacity in both healthy and DS cultures, suggesting that the treatment might need concentration and duration adjustments. This study not only shows that cellular senescence prevails in DS patient-derived cell cultures, but also that it aggravates with advancing age. Furthermore, the study suggests senolysis as a potential therapy to prevent or delay the onset of progeroid clinical features associated with trisomy 21, eventually extending DS patients’ healthspan(definition).

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
Canonical
link ↗
Fetched
2026-10-30 MST

Cite this

APA
Silva, R.A.D. (2021). Effect of senolytic anti-aging compounds in Down syndrome-driven senescence. <em>Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)</em>. https://openalex.org/W3206173870
Vancouver
Silva RAD. Effect of senolytic anti-aging compounds in Down syndrome-driven senescence. Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT). 2021.
BibTeX
@unpublished{raquel2021Effect, title = {Effect of senolytic anti-aging compounds in Down syndrome-driven senescence}, author = {Raquel Alves da Silva}, journal = {Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)}, year = {2021}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings